Celegen Corporation’s Revlimid Combo Fails as Prostate Cancer Therapy
Celegen Corporation‘s Revlimid Combo Fails as Prostate Cancer Therapy
Adding lenalidomide (Revlimid) to the chemotherapy regimen led to greater toxicity and worse survival in patients with untreated castration-resistant prostate cancer (CRPC), results of a large international trial showed. Men randomized to a regimen of lenalidomide, docetaxel, and prednisone, had a 53% increased mortality hazard, a 32% greater hazard for progression, and significantly higher rates of neutropenia, febrile neutropenia, and multiple non-hematologic adverse events.
Source Article:
http://www.medpagetoday.com/HematologyOncology/ProstateCancer/35100
